STATEN ISLAND, N.Y., May 11, 2022 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and…
Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update
